|Year : 2021 | Volume
| Issue : 4 | Page : 223-227
Results of injection sclerotherapy with bleomycin in pediatric lymphatic malformations
Vipan Kumar1, Subhasis Roy Choudhury1, Partap Singh Yadav1, Vikram Khanna1, Amit Gupta1, Rajiv Chadha1, Rama Anand2
1 Department of Pediatric Surgery, Lady Hardinge Medical College and Kalawati Saran Childrens Hospital, New Delhi, India
2 Department of Radiology, Lady Hardinge Medical College and Kalawati Saran Childrens Hospital, New Delhi, India
|Date of Submission||06-Apr-2020|
|Date of Decision||11-May-2020|
|Date of Acceptance||19-Jun-2020|
|Date of Web Publication||12-Jul-2021|
Prof. Subhasis Roy Choudhury
Department of Pediatric Surgery, Lady Hardinge Medical College and Kalawati Saran Childrens Hospital, New Delhi
Source of Support: None, Conflict of Interest: None
| Abstract|| |
Aim: The aim of the study was to evaluate the results of injection sclerotherapy with bleomycin in pediatric patients with lymphatic malformations.
Materials and Methods: In this prospective cohort study, all consenting pediatric patients with macrocystic lymphatic malformations were managed with injection bleomycin sclerotherapy (0.5 mg/kg, not exceeding 5 mg at a time) under ultrasound (US) guidance. After aspirating the cyst fluid bleomycin was instilled intralesionally in a ratio of 5:1 (aspirated cyst fluid volume: diluted bleomycin solution volume). Patients were reassessed at three weekly intervals. The response to therapy was assessed clinically as well as by size and volume on ultrasound Doppler study. The response was classified as excellent response, i.e., complete regression, good response >50% regression, and poor response <50% regression.
Results: Sixty patients with lymphatic malformations were enrolled in the study, the mean age was 3.22 years, and the male-to-female was 2.5:1. The most common site of lesion was in the neck (43.3%), followed by the axilla (15%) and flank (8.3%). The responses were excellent, good, and poor in 43 (71.6%), 12 (20%), and five (8.3%) patients, respectively. Two patients underwent surgical excision of the residual lesion. Complications noted were fever in six, local pain in five, and residual lesion in three patients.
Conclusion: Sclerotherapy with bleomycin is simple, safe, and effective in the first line of management for macrocystic lymphatic malformations in children.
Keywords: Bleomycin, lymphatic malformations, sclerotherapy
|How to cite this article:|
Kumar V, Choudhury SR, Yadav PS, Khanna V, Gupta A, Chadha R, Anand R. Results of injection sclerotherapy with bleomycin in pediatric lymphatic malformations. J Indian Assoc Pediatr Surg 2021;26:223-7
|How to cite this URL:|
Kumar V, Choudhury SR, Yadav PS, Khanna V, Gupta A, Chadha R, Anand R. Results of injection sclerotherapy with bleomycin in pediatric lymphatic malformations. J Indian Assoc Pediatr Surg [serial online] 2021 [cited 2021 Sep 24];26:223-7. Available from: https://www.jiaps.com/text.asp?2021/26/4/223/321198
| Introduction|| |
Lymphatic malformations (LMs) are slow-flow vascular anomalies of the lymphatic system, occurring in 1 of 2000–4000 live births. Most of them are evident at birth (65%), while the remainders become evident by the age of 2 years. They occur in nearly all regions of the body but are most frequently seen in the head and neck (75%), axilla (20%), and inguinal areas (2%). The most common mode of presentation is asymptomatic swelling; however, they can cause symptoms due to compression or pressure effects on neighboring structures.
Histologically, LMs are composed of thin-walled irregular lymphatic channels of varying size lined with lymphatic endothelial cells., The cysts are filled with protein-rich fluid containing lymphocytes and macrophages. Based on the diameter of the cyst, they have been characterized into macrocystic (diameter >1 cm), microcystic (diameter <1 cm), or mixed cystic lesions.
The mainstay of therapy is surgical excision, but due to its nature of extending across anatomical regions and infiltration along important anatomical structures (nerves and vessels), total excision is not always feasible. Extensive surgery often leads to disfigurement, damage to vital structures, and ugly scarring. To avoid the morbidity associated with surgical excision, serial aspirations and injection of sclerosing agents have been used with satisfactory results. They act by producing nonspecific inflammatory reaction., Some of the commonly used sclerosants are doxycycline, ethanol, bleomycin, and sodium tetradecyl sulfate; however, there is no proven superiority of one agent over the other. We set up to study the safety and efficacy of injection bleomycin sclerotherapy for the treatment of macrocystic LMs in children.
| Materials and Methods|| |
This was a prospective observational cohort study conducted in the department of pediatric surgery and the department of radiology of a tertiary care children's hospital between December 2016 and October 2018. All pediatric patients with LMs were enrolled in the study. Patients with microcystic LM and lesions extending into the mediastinum, lesions around the trachea, infected lesions, and deep retroperitoneal lesions were excluded from injection sclerotherapy.
After obtaining ethical clearance and informed parental consent, a standard protocol for bleomycin sclerotherapy was followed. Each vial of bleomycin having 15 units, i.e., equivalent to 15 mg, was diluted with 5 ml of sterile water for injection constituting a solution of 3 mg per ml. This was further diluted as required. The dose of bleomycin injected was 0.5 mg/kg body weight and not exceeding 5 mg at a time. Injections were given under ultrasound (US) guidance in the department of radiology by pediatric surgeons. Puncture and aspiration of all possible cysts was done with a 21 G needle followed by instillation of intralesional bleomycin in each one in a ratio of 5:1 of the constituted solution (aspirated cyst fluid volume: diluted bleomycin solution volume) [Figure 1]. Wherever possible, post-procedure compression was applied. The patients were kept under observation for 3 h post sclerotherapy. Oral paracetamol was prescribed for pain and fever post sclerotherapy. Patients were reviewed after 3 weeks for evaluation of the response and any need for further sclerotherapy. The response was assessed as excellent, i.e., complete regression, good >50% regression, and poor <50% regression. The response was assessed clinically by the reduction in size in comparison to previous records and photographs and on the basis of color Doppler US by the reduction in size as well as volume. Depending on the response, repeat sclerotherapy was given if required at an interval of 3 weeks with a maximum of four sessions. The final evaluation of the response was recorded during the follow-up visit. The post-sclerotherapy residual lesions if any were managed with either surgical intervention or observation depending on the size, site, response, and patient preference.
|Figure 1: (a and b) Ultrasound-guided aspiration and sclerotherapy of large lymphatic cyst|
Click here to view
Outcome variables studied were total number of sclerotherapy sessions required for the response of the lesion, proportion of patients with complications if any, and proportion of patients requiring post-sclerotherapy surgical management.
The analysis was performed using the Statistical Package for the Social Sciences (IBM SPSS 25.0. Armonk,NY : IBM Corp.). Statistical significance for qualitative data was assessed with “Chi-square test,” while for quantitative data, it was done using Student's t-test.
| Results|| |
In this study, 60 pediatric patients with LMs were prospectively enrolled from December 2016 to October 2018. Majority of the patients were <3 years of age (n = 37; 61.7%), followed by 3–9 years of age (n = 19; 31.7%).The mean age was 3.22 ± 3.39 years and male-to-female ratio was 2.5:1. The neck was the most common site of lesions (n = 26; 43.3%), followed by the axilla (n = 9; 15%), flank (n = 5; 8.3%), chest wall (n = 4; 6.7%), suboccipital region (n = 3;5%), and very few on other sites [Table 1].
The number of patients receiving one, two, three, and four sessions of sclerotherapy were 60 (100%), 51 (85%), 34 (56.6%), and 19 (31.6%), respectively. The grading of response with sessions of sclerotherapy is shown in [Figure 2].
|Figure 2: Grading of response with a number of sessions of sclerotherapy|
Click here to view
Overall, 55/60 (91.6%) showed satisfactory response to bleomycin sclerotherapy. Complete resolution to sclerotherapy, i.e., excellent response, was observed in 71.6%, (n = 43), good response in 20%, (n = 12), and poor response in 8.3%, (n = 5), respectively [Table 2] and [Figure 3]. Twelve patients (20%) had complications in the form of fever (n = 6; 10%), pain (n = 5; 8.3%), and residual lesion (n = 3;5%) [Table 2]. No complication was noted following the first session of sclerotherapy, but some occurred in the subsequent sessions. None of the patients developed enlargement of size, bleeding, skin discoloration, or scarring following the sclerotherapy.
|Figure 3: (a) Pre- and (b) post bleomycin sclerotherapy response of a lymphatic malformation|
Click here to view
Clinically, the size of lesions included in this study ranged from 2 cm to 24 cm; the mean size was 5.89 cm. The US measured size and volume ranged from 1.7 cm and 1.4 cm3 to 20 cm and 38 cm3, mean being 4.74 cm and 5.82 cm3. The mean clinical size (maximal dimension) of lesions that responded to treatment with one to four sessions of sclerotherapy was 2.5 cm, 4.1 cm, 5.4 cm, and 9.44 cm, respectively. The difference between the size of lesions and the number of sessions of sclerotherapy required was statistically significant (P < 0.001). The mean US measured size and volume of lesions that responded with one to four sessions of sclerotherapy was 1.9 cm and 1.7 cm3; 3.1 cm and 3.05 cm3; 4.38 cm and 5.06 cm3, and 7.7 cm and 10.52 cm3, respectively. The difference between the size and volume of the lesions as measured using US, and the number of sessions of sclerotherapy required was statistically significant (P < 0.001). One patient with chest wall lesion had a good response to sclerotherapy; however, he opted for surgery, while other patients with good responses opted for observation. One patient with neck lesion had a poor response to sclerotherapy and underwent surgical excision. Four patients with lesions at the suprascapular, forehead, chest, and suboccipetal regions had a poor response to sclerotherapy but choose for further observation of the residual lesion. There was weak statistical significance noted between different sites of lesion and response to sclerotherapy [P = 0.045, [Table 1]].
| Discussion|| |
LMs are frequently seen in children. The most common location reported is the head-and-neck region, similar to our finding (43.3%). Treatment options can vary from observation to sclerotherapy to surgical excision. However, no clear treatment algorithm is currently available. Optimal treatment is to restore function and cosmesis. In the absence of any strong evidence in the literature, the choice of treatment depends on the treating team, the type and site of the lesion, and preference of the family. Although surgical excision is a definitive treatment for LMs, it may be difficult at times because of the infiltrative nature of the lesions. These thin-walled lesions often do not respect tissue planes leading to a high incidence of complications (12%–23%) like vital organ injuries, nerve injuries, bleeding, infection scar formation, and recurrences ranging from 15-53%., In a retrospective cohort study comparing primary surgery versus primary sclerotherapy in LMs, Balakrishnan et al. found no statistically significant difference in effectiveness after the first intervention or at 1 year. Sclerotherapy is a simpler alternative to tedious surgical excision treatment and avoids the complications related to the surgery. Various sclerosants are available for the treatment of LMs. The results seen with most of the agents are comparable. The reported success rates with injection bleomycin, doxycycline, picibanil (OK 432), and sodium tetradecyl sulfate are between 84% and 90%., Picibanil is currently not Food and Drug Administration approved, sodium tetradecyl sulfate has a higher risk of infections, and doxycycline causes tooth discoloration and mainly works on macrocystic lesions. We have been using bleomycin as it is reported to be effective in macrocystic and some microcystic LMs; it is easily available with satisfactory response rate and has minimal side effects. Complications of bleomycin include mild flu-like symptoms, erythema, edema, and pigmentation which are minor in nature. It is important to keep the dose of bleomycin at 0.5 mg/kg and not exceeding 5 mg at a time to avoid any dose-related toxicity. The systemic complication of pulmonary fibrosis does not occur with the above dose of injection sclerotherapy recommended for the treatment of LMs, as shown in a systematic review and meta-analysis.
The mean age of patients in our study was 3.22 ± 3.39 years, youngest being 11 days and the oldest being 15 years similar to most of the reports., Post sclerotherapy, no major injection-related event or complication occurred. Oral paracetamol was found to be effective for control of pain and fever. The procedure under sedation is preferred for accurate drug delivery, although we avoided intravenous sedation and managed them on an outpatient basis., Patients were reviewed after 3 weeks for assessment of response and repeat sclerotherapy was given if deemed necessary for a maximum of four sessions.
The response was graded as excellent, good, and poor as per the report of Rozman et al. The overall satisfactory response rate of 91.6% in this study fared better than most of the reported series,,, [Table 3]. Size and volume of the lesions correlated with the number of injection sessions required, as larger lesions required more sessions of sclerotherapy.
|Table 3: Comparison of results of bleomycin injection sclerotherpy for lymphatic malformations|
Click here to view
The probable reason of our higher success rate can be attributed to selective inclusion of macrocystic lesion and exclusion of mediastinal lesions, lesions around the trachea with respiratory distress, infected lesions, and deep retroperitoneal lesions as they generally respond poorly to injection sclerotherapy. Furthermore, ultrasound-guided aspiration and sclerosant therapy used by us resulted in accurate drug delivery leading to a good response. Lesions showing poor response were located in the forehead, neck, chest, suprascapular, and suboccipital regions. Complications observed in our study in the form of fever (10%), tenderness (8.3%), and residual fibrosis (5%) are comparable to similar studies., Residual lesions post sclerotherapy can be effectively managed by surgery if deemed necessary. Sirolimus has recently been found to be effective in the management of complex LMs due to their anti-lymphangiogenetic properties. A lacuna of our study is the lack of comparison with other modes of therapy. A randomized control trial including various agents used for sclerotherapy in LMs would be more appropriate to validate the role of each one; however, it would require a large number of patients with longer duration of the study.
| Conclusion|| |
LMs in children require careful selection of procedure from less invasive sclerotherapy to surgical excision or combinations of therapy as definitive treatment. The results of our study reveal that sclerotherapy with injection bleomycin as the first line of treatment in the macrocystic variety has a very good response rate with minimal complications.
Declaration of patient consent
The authors certify that they have obtained all appropriate patient consent forms. In the form the patient(s) has/have given his/her/their consent for his/her/their images and other clinical information to be reported in the journal. The patients understand that their names and initials will not be published and due efforts will be made to conceal their identity, but anonymity cannot be guaranteed.
Financial support and sponsorship
Conflicts of interest
There are no conflicts of interest.
| References|| |
Kennedy TL, Whitaker M, Pellitteri P, Wood WE. Cystic hygroma/lymphangioma: A rational approach to management. Laryngoscope 2001;111:1929-37.
Giguère CM, Bauman NM, Smith RJ. New treatment options for lymphangioma in infants and children. Ann Otol Rhinol Laryngol 2002;111:1066-75.
Sabin FR. The lymphatic system in human embryos, with a consideration of the morphology of the system as a whole. Am J Anat 1909;9:43-91.
Fevurly RD, Fishman SJ. Vascular anomalies in pediatrics. Surg Clin North Am 2012;92:769-800, x.
|5.|et al. Comparative analysis of D2-40 and LYVE-1 immunostaining in lymphatic malformations. Lymphology 2008;41:103-10.
Bruder E, Perez-Atayde AR, Jundt G, Alomari AI, Rischewski J, Fishman SJ, et a
l. Vascular lesions of bone in children, adolescents, and young adults. A clinicopathologic reappraisal and application of the ISSVA classification. Virchows Arch 2009;454:161-79.
Wassef M, Blei F, Adams D, Alomari A, Baselga E, Berenstein A, et al
. Vascular anomalies classification: Recommendations from the international society for the study of vascular anomalies. Pediatrics 2015;136:e203-14.
Waner M, Suen JY. Treatment options for the management of vascular malformations. Hemangiomas and vascular malformations of the head and neck. New York: Wiley-Liss. 1999. p. 315-50.
Defnet AM, Bagrodia N, Hernandez SL, Gwilliam N, Kandel JJ. Pediatric lymphatic malformations: Evolving understanding and therapeutic options. Pediatr Surg Int 2016;32:425-33.
Okada A, Kubota A, Fukuzawa M, Imura K, Kamata S. Injection of bleomycin as a primary therapy of cystic lymphangioma. J Pediatr Surg 1992;27:440-3.
Charabi B, Bretlau P, Bille M, Holmelund M. Cystic hygroma of the head and neck-a long-term follow-up of 44 cases. Acta Otolaryngol Suppl 2000;543:248-50.
Balakrishnan K, Menezes MD, Chen BS, Magit AE, Perkins JA. Primary surgery vs. primary sclerotherapy for head and neck lymphatic malformations. JAMA Otolaryngol Head Neck Surg 2014;140:41-5.
Ardıçlı B, Karnak İ, Çiftçi AÖ, Tanyel FC, Şenocak ME. Sclerotherapy with bleomycin versus surgical excision for extracervical cystic lymphatic malformations in children. Surg Today 2016;46:97-101.
Tu JH, Do HM, Patel V, Yeom KW, Teng JM. Sclerotherapy for lymphatic malformations of the head and neck in the pediatric population. J Neurointerv Surg 2017;9:1023-6.
Farnoosh S, Don D, Koempel J, Panossian A, Anselmo D, Stanley P. Efficacy of doxycycline and sodium tetradecyl sulfate sclerotherapy in pediatric head and neck lymphatic malformations. Int J Pediatr Otorhinolaryngol 2015;79:883-7.
Yoo JC, Ahn Y, Lim YS, Hah JH, Kwon TK, Sung MW, et al
. OK-432 sclerotherapy in head and neck lymphangiomas: long-term follow-up result. Otolaryngol Head Neck Surg 2009;140:120-3.
Bai Y, Jia J, Huang XX, Alsharif MJ, Zhao JH, Zhao YF. Sclerotherapy of microcystic lymphatic malformations in oral and facial regions. J Oral Maxillofac Surg 2009;67:251-6.
Horbach SE, Rigter IM, Smitt JH, Reekers JA, Spuls PI, van der Horst CM. Intralesional bleomycin injections for vascular malformations: A systematic review and meta-analysis. Plast Reconstr Surg 2016;137:244-56.
Rozman Z, Thambidorai RR, Zaleha AM, Zakaria Z, Zulfiqar MA. Lymphangioma: Is intralesional bleomycin sclerotherapy effective? Biomed Imaging Interv J 2011;7:e18.
Saha AK, Haque SS, Islam KM. Effect of intralesional bleomycin as an alternative therapy for cystic hygroma. Bang Med J Khulna 2013;46:12-5.
Tanigawa N, Shimomatsuya T, Takahashi K, Inomata Y, Tanaka K, Satomura K, et al
. Treatment of cystic hygroma and lymphangioma with the use of bleomycin fat emulsion. Cancer 1987;60:741-9.
Orford J, Barker A, Thonell S, King P, Murphy J. Bleomycin therapy for cystic hygroma. J Pediatr Surg 1995;30:1282-7.
Zulfiqar MA, Zaleha AM, Zakaria Z, Amin T. The treatment of neck lymphangioma with intralesional injection of bleomycin. Med J Malaysia 1999;54:478-81.
Mahajan JK, Bharathi V, Chowdhary SK, Samujh R, Menon P, Rao KL. Bleomycin as intralesional sclerosant for cystic hygromas. J Indian Assoc Pediatr Surg 2004;9:3-7. [Full text]
Kumar V, Kumar P, Pandey A, Gupta DK, Shukla RC, Sharma SP, et al
. Intralesional bleomycin in lymphangioma: an effective and safe non-operative modality of treatment. J Cutan Aesthet Surg 2012;5:133-6.
] [Full text]
Jain V, Mohta M, Senger M, Bansal K, Valvi K. Use of intralesional bleomycin as primary therapy in macro cystic lymphangiomas. Indian J Dermatol Venerol Leprol 2013;79:524-5.
Sonmez K, Karabulut R, Turkyilmaz Z. Macrocystic lymphangioma in children treated by sclerotherapy with bleomycin. J Craniofac Surg 2020;31:e250-1.
Strychowsky JE, Rahbar R, O'Hare MJ, Irace AL, Padua H, Trenor CC 3rd
. Sirolimus as treatment for 19 patients with refractory cervicofacial lymphatic malformation. Laryngoscope 2018;128:269-76.
[Figure 1], [Figure 2], [Figure 3]
[Table 1], [Table 2], [Table 3]